Loading
A phase 1/2 trial of JAB-8263 in non-small-cell lung cancer, small-cell lung cancer and ovarian cancer, run by Jacobio Pharmaceuticals Co., Ltd., now recruiting.
A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors is a phase 1/2 interventional study registered as NCT04686682 by Jacobio Pharmaceuticals Co., Ltd., with 152 participants planned, started 2021-05-07 and due to reach its primary completion in 2028-01. Interventions recorded: JAB-8263.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Jacobio Pharmaceuticals, Small-cell lung cancer and the tag pipeline.
Shares Jacobio Pharmaceuticals and the tag pipeline.
Shares Jacobio Pharmaceuticals and the tag pipeline.
Shares Jacobio Pharmaceuticals and the tag pipeline.
Shares Ovarian cancer, Small-cell lung cancer and the tag pipeline.
Shares Jacobio Pharmaceuticals and the tag pipeline.
Shares Small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/